The company's Life Sciences segment was up 17 percent year over year, while its Diagnostics business grew 8 percent.
IDT will operate as a standalone company within Danaher's Life Sciences segment after the close of the deal, which is expected to occur in mid-2018.
Aldevron will manufacture IDT's patented S. pyogenes HiFi Cas9 mutant for research, clinical, and commercial uses.
The companies will develop a portfolio of indexed adapters specifically designed for multiplex NGS and optimized for use on Illumina systems such as the NovaSeq.
The agreement provides researchers with local customer care, and allows them to order reagents from within the country rather than importing them.
The technology has been a core capability of the firm, which is expanding its suite of products to address the broader needs of genomics researchers.
The acquisition of GeneWorks' oligo business widens IDT's reach in the Asia-Pacific region, the company said.
IDT has licensed the CRISPR/Cpf1 RNA-guided editing system from the Broad Institute and intends to sell it to pharmaceutical and other commercial labs.
The Hereditary Cancer Solution combines target capture probes from Integrated DNA Technologies with specialized analytics developed by Sophia.
The acquisition of San Diego-based ValueGene expands IDT's presence in Southern California.
Researchers find that historical factors influence which genes are the most highly studied, the Atlantic reports.
The US National Science Foundation's new sexual harassment policy is to go into effect next month, according to Nature News.
Researchers report using genotyping to tie together illegal ivory shipments and trace them back to a handful of cartels, the New York Times reports.
In Nature this week: genomic ancestry analysis of Sardinians, current noncoding mutations in colorectal cancer, and more.